Xentuzumab Recombinant Human Monoclonal Antibody, Invitrogen™

Description

• Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles
• Store at 2 to 8 °C for one week
• Store at -20 to -80 °C for twelve months from the date of receipt
• Xentuzumab is a biosimilar that targets IGF1
• IGF1 (Insulin-like growth factor-1) is structurally and functionally related to insulin but has a much higher growth-promoting activity
• A variety of cellular responses are induced by IGF1, including cell proliferation, differentiation, migration, and survival
• Further, IGF1 is a polypeptide growth factor that stimulates the proliferation of a wide range of cell types in muscle, bone, and cartilage tissue
• IGF1 stimulates glucose transport in rat bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin, not only regarding glycogen and DNA synthesis but also with regards to enhancing glucose uptake
• In circulation, IGFs are predominantly bound to binding proteins (IGFBPs) which prolong the half-life of the IGFs and play a role in delivering them to target tissues
• IGF-I is known as one of the most potent activators of the AKT signaling pathway which is known to be a stimulator of proliferation and an inhibitor of programmed cell death
• Moreover, mature human IGF-I is 100% homologous with bovine and porcine proteins
• Low levels of IGF1 have been linked to Alzheimer's disease
• IGF1 is processed from a precursor, bound by a specific receptor, and secreted
• Defects in the IGF1 gene are a cause of insulin-like growth factor 1 deficiency and several transcript variants encoding different isoforms have been found.